Research and Development of a Second-Generation Process for Oseltamivir Phosphate, Prodrug for a Neuraminidase Inhibitor
Organic Process Research & Development2003Vol. 8(1), pp. 86–91
Citations Over TimeTop 16% of 2003 papers
Abstract
A second-generation manufacturing process from a shikimic acid-derived epoxide to oseltamivir phosphate features a magnesium chloride−amine complex-catalyzed ring opening of the epoxide by tert-butylamine, a selective O-sulfonylation of the resulting tert-butylamino alcohol, a surprisingly efficient cleavage of a tert-butyl group from an aliphatic tert-butylamide, and the isolation of oseltamivir phosphate from a palladium-catalyzed allyl transfer reaction mixture. The overall yield from the epoxide to oseltamivir phosphate has been increased from 27 to 29% or 35−38% for two previous processes, respectively, to 61%.
Related Papers
- → Reduced Effectiveness of Oseltamivir in Children Infected With Oseltamivir-resistant Influenza A (H1N1) Viruses With His275Tyr Mutation(2010)52 cited
- Use of oseltamivir in children.(2009)
- → Prodrugs to Codrugs(2017)3 cited
- → Concept of Prodrug(2015)1 cited
- The progress of antitumor prodrug in target tumor therapy(2007)